Trajectory patterns and cumulative burden of CEA during follow-up with non-small cell lung cancer outcomes: A retrospective longitudinal cohort study

被引:2
|
作者
Li, Chunxia [1 ]
Liu, Lizhu [2 ]
You, Ruimin [2 ]
Li, Yanli [2 ]
Pu, Hongjiang [3 ]
Lei, Ming [4 ]
Fan, Bingbing [1 ]
Lv, Jiali [1 ]
Liu, Mengmei [5 ]
Yan, Guanghong [5 ]
Li, Zhenhui [2 ]
You, Dingyun [5 ,6 ]
Zhang, Tao [1 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Biostat, Jinan 250012, Shandong, Peoples R China
[2] Kunming Med Univ, Affiliated Hosp 3, Yunnan Canc Hosp, Dept Radiol,Yunnan Canc Ctr, Kunming 650118, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 3, Yunnan Canc Hosp, Dept Colorectal Surg,Yunnan Canc Ctr, Kunming 650118, Peoples R China
[4] Kunming Med Univ, Affiliated Hosp 3, Yunnan Canc Hosp, Dept Clin Lab Med,Yunnan Canc Ctr, Kunming 650118, Peoples R China
[5] Kunming Med Univ, Sch Publ Hlth, Kunming 650500, Yunnan, Peoples R China
[6] Kunming Med Univ, Yunnan Prov Key Lab Publ Hlth & Biosafety, Kunming 650500, Yunnan, Peoples R China
基金
中国国家自然科学基金;
关键词
SERUM CARCINOEMBRYONIC ANTIGEN; PROGNOSTIC-SIGNIFICANCE; SURGERY; LEVEL;
D O I
10.1038/s41416-024-02678-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundPrevious studies of non-small cell lung cancer (NSCLC) focused on CEA measured at a single time point, ignoring serial CEA measurements.MethodsThis retrospective cohort included 2959 patients underwent surgery for stage I-III NSCLC. CEA trajectory patterns and long-term cumulative CEA burden were evaluated using the latent class growth mixture model.ResultsFour CEA trajectory groups were identified, named as low-stable, decreasing, early-rising and later-rising. Compared with the low-stable group, the adjusted hazard ratios associated with death were 1.27, 4.50, and 3.68 for the other groups. Cumulative CEA burden were positively associated with the risk of death in patients not belonging to the low-stable group. The 5-year overall survival (OS) rates decreased from 62.3% to 33.0% for the first and fourth quantile groups of cumulative CEA burden. Jointly, patients with decreasing CEA trajectory could be further divided into the decreasing & low and decreasing & high group, with 5-year OS rates to be 77.9% and 47.1%. Patients with rising CEA trajectory and high cumulative CEA were found to be more likely to develop bone metastasis.ConclusionsLongitudinal trajectory patterns and long-term cumulative burden of CEA were independent prognostic factors of NSCLC. We recommend CEA in postoperative surveillance of NSCLC.
引用
收藏
页码:1803 / 1808
页数:6
相关论文
共 50 条
  • [21] Serum Human Epididymis Protein 4 (HE4) As A Diagnostic And Follow-Up Biomarker in Patients With Non-Small Cell Lung Cancer
    Kumbasar, Ulas
    Dikmen, Zeliha G.
    Yilmaz, Yigit
    Ancin, Burcu
    Dikmen, Erkan
    Dogan, Riza
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2017, 27 (03): : 137 - 142
  • [22] Role of invasive mediastinal nodal staging in survival outcomes of patients with non-small cell lung cancer and without radiologic lymph node metastasis: a retrospective cohort study
    Kim, Hong Kwan
    Jeon, Yeong Jeong
    Um, Sang -Won
    Shin, Sun Hye
    Jeong, Byeong-Ho
    Lee, Kyungjong
    Kim, Hojoong
    Lee, Ho Yun
    Kim, Tae Jung
    Lee, Kyung Soo
    Choi, Yoon-La
    Han, Joungho
    Ahn, Yong Chan
    Pyo, Hongryull
    Noh, Jae Myoung
    Choi, Joon Young
    Cho, Jong Ho
    Choi, Yong Soo
    Zo, Jae Ill
    Shim, Young Mog
    Hwang, Seung-sik
    Kim, Jhingook
    ECLINICALMEDICINE, 2024, 69
  • [23] Surgical treatment of non-small cell lung cancer with mediastinal node invasion.: A retrospective study
    Obrer, AA
    Díaz, EM
    Alonso, DP
    Mira, FR
    Juan, AC
    Gil, AG
    Pendería, SR
    Armengod, AC
    ARCHIVOS DE BRONCONEUMOLOGIA, 2001, 37 (03): : 121 - 126
  • [24] Prognostic factors and predictive model construction in patients with non-small cell lung cancer: a retrospective study
    Ma, Shixin
    Wang, Lunqing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [25] Radiotherapy versus follow-up in the treatment of pathological stage Ia and Ib non-small cell lung cancer. Early stopped analysis of a randomized controlled study
    Granone, P
    Trodella, L
    Margaritora, S
    Cesario, A
    Corbo, GM
    Mantini, G
    Balducci, M
    Fumagalli, G
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2000, 18 (04) : 418 - 424
  • [26] Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer
    Ozeki, Naoki
    Fukui, Takayuki
    Taniguchi, Tetsuo
    Usami, Noriyasu
    Kawaguchi, Koji
    Ito, Simon
    Sakao, Yukinori
    Mitsudomi, Tetsuya
    Hirakawa, Akihiro
    Yokoi, Kohei
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2014, 45 (04) : 687 - 692
  • [27] Efficacy and safety of neoadjuvant tislelizumab combined with chemotherapy in locally advanced non-small cell lung cancer-a retrospective cohort study
    Chen, Hao
    Zhang, Jiarong
    Chen, Chun
    Zheng, Wei
    Zheng, Bin
    JOURNAL OF THORACIC DISEASE, 2024, 16 (01) : 498 - 506
  • [28] Influencing Factors on the Quality of Lymph Node Dissection for Stage IA Non-Small Cell Lung Cancer: A Retrospective Nationwide Cohort Study
    Gabryel, Piotr
    Skrzypczak, Piotr
    Roszak, Magdalena
    Campisi, Alessio
    Zielinska, Dominika
    Bryl, Maciej
    Stencel, Katarzyna
    Piwkowski, Cezary
    CANCERS, 2024, 16 (02)
  • [29] Prospective cohort study of Suture-Line recurrence and clinical outcomes in stage 1A Non-Small cell lung cancer
    Gros, Louis
    Yip, Rowena
    Flores, Raja M.
    Zhang, Jiafang
    Paksashvili, Natela
    Zhang, Lijing
    Lyu, Lyu
    Cai, Siyang
    Taioli, Emanuela
    Yankelevitz, David F.
    Henschke, Claudia I.
    IELCART Investigators, I. E. L. C. A. R. T.
    LUNG CANCER, 2025, 202
  • [30] Value of 18F FDG-PET/CT parameters on long term follow-up for patients with non-small cell lung cancer
    Zoair, Mohammed
    Taber, Samantha
    Bittner, Roland
    Foerster, Gregor
    Griff, Sergej
    Bauer, Torsten T.
    Pfannschmidt, Joachim
    INNOVATIVE SURGICAL SCIENCES, 2022, 7 (02): : 35 - 43